Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression

Abstract

The letter about the article “Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study” that discusses some points about methodology, outcome measures, and results.

Keywords

ketamine TRD scales

Get full access to this article

View all access options for this article.

References

Glue

Neehoff

Beaglehole

, et al. (2024) Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. J Psychopharmacol 38: 162–167. DOI: 10.1177/02698811241227026.

Mitchell

Meader

Symonds

(2010) Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: A meta-analysis. J Affect Disorders 126: 335–348. DOI: 10.1016/j.jad.2010.01.067.

Zhou

Sun

Zhang

, et al. (2021) Ketamine alleviates depressive symptoms in patients undergoing intracranial tumor resection: A randomized controlled trial. Anesth Analg 133: 1588–1597. DOI: 10.1213/ANE.0000000000005752.